Navigation Links
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Date:8/28/2008

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:

BioCentury Newsmakers in the Biotech Industry

Thursday, September 4, 2008, 10:00 AM Eastern time

Millennium Broadway Hotel, New York

UBS Global Life Sciences Conference

Tuesday, September 23, 2008, 9:30 AM Eastern time

Grand Hyatt Hotel, New York

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
2. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Pixel Bridge Works With Anika Therapeutics to Launch New Website
8. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
9. Arno Therapeutics Announces Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Magellan Biosciences, a global manufacturer of products designed ... labor intensive, announced that its Vice President of Business ... featured speaker at the Medicaid Health Plans of America ... takes place tomorrow in Washington, DC. Mr. De Jesus ...
... 17, 2011 Anaphore Inc. today announced that Katherine Bowdish, ... overview at the 13th Annual C21 BioVentures conference. The presentation ... at The Meritage Resort in Napa, Calif.   ... is developing a new class of protein pharmaceuticals to address ...
... PERTH, Australia, May 17, 2011 Australian supplier of ... an exclusive distributor agreement with a leading Japanese Life ... Taiwan, China and South Korea. Headquartered in ... in the chemical, pharmaceutical and biotechnology industries and have ...
Cached Biology Technology:Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 2Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 3Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 4Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 5Magellan Biosciences to Present at Medicaid Health Plans of America Center for Best Practices First Annual Awards Forum 6Anaphore to Present Company Overview with Focus on Atrimer Technology Platform at 13th Annual C21 BioVentures Conference 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 2Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea 3
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... COLUMBIA, Mo. Studies show the incidence of diabetes in ... Now, University of Missouri veterinarians have changed the way veterinarians ... monitor glucose in humans. Dogs are susceptible to type ... in their bloodstream because their bodies do not produce enough ...
... is often referred to as the land of opportunity. ... of opportunity." NJIT gave him the opportunity, for instance, ... distinguished professor in the department of physics. Naqvi started the ... his research recently helped him win a Goldwater Scholarship ...
... Ohio Mosquitoes make proteins to help them handle the ... blood meals, a new study has found. The mosquito,s ... finding warm-blooded hosts, avoiding detection, penetrating tough skin and evading ... a human hand. Until now, the stress of the ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Third brother wins gold at NJIT 2Study shows how mosquitoes handle the heat of a hot blood meal 2Study shows how mosquitoes handle the heat of a hot blood meal 3
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
... The 500 optimization kit is for fine-tuning ... interest. The kit is recommended when you ... system. The kit includes 0.25 g each ... micrometer diameter gold microcarriers, 100 each of ...
... Serial Analysis of Gene Expression (SAGE) ... technology. Agencourt offers a cost-effective outsourcing ... and LongSAGE libraries. Agencourt's SAGE sequencing ... project turnaround and long Phred20 read ...
Biology Products: